The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
04-Oct-16
$223 million
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
Target:
US rights to Toprol-XL (AstraZeneca)
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
15-Dec-10
$12.9 billion
![USA/Switzerland U.S.A., Swiss flags](https://www.greenhill.com/sites/default/files/usa_swiss.gif)
Target:
Alcon, Inc.
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
08-Jan-10
$134 million
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Target:
Minerva plc
Acquiror:
KiFin Limited
Advised Minerva plc, a UK real estate development company, on its successful defence following an unsolicited offer from KiFin Limited, a company that makes investments for the benefit of Mr Nathan Kirsh